MR1-restricted T cells: the new dawn of cancer immunotherapy

Cancer immunotherapy has recently undergone rapid development into a validated therapy for clinical use. The adoptive transfer of engineered autologous T cells, such as chimeric antigen receptor (CAR) T cells, has been remarkably successful in patients with leukemia and lymphoma with cluster of diff...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhiding, Wang, Mengzhen, Chen, Jinghong, Zhang, Linlin, Zhang, Li, Yu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2020
Materias:
Immunology & Inflammation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670570/
https://www.ncbi.nlm.nih.gov/pubmed/33185693
http://dx.doi.org/10.1042/BSR20202962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670570/
https://www.ncbi.nlm.nih.gov/pubmed/33185693
http://dx.doi.org/10.1042/BSR20202962

Ejemplares similares